An observational study in Brain Tumor, Stroke, Acute and Brain Aneurysm, sponsored by Rutgers, The State University of New Jersey. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Rutgers, The State University of New Jersey · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,443 studies in Brain Neoplasms with a site in United States — 229 open to participants now, 352 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 89th largest by enrollment of the 191 observational ones that give a count, is one of 43 that started in 2020, is one of 193 observational ones, and was the 1,139th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →229 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
Adriana Fonseca · Sites in United States
Ages up to 45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 424 Brain Neoplasms studies recruiting now, 285 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,443 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 552 · Phase 2 520 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 43 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,188 interventional studies, 76 across the 191 observational. Of the 993 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,443 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 506 studies on the registry; 131 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,443 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this single arm study is to evaluate the safety and feasibility of the AXS Infinity LS (Stryker, Freemont, CA, USA) and AXS Infinity LS Plus (Stryker, Freemont, CA, USA) catheters during the transradial approach through a secondary use of the data collected during neurointerventional procedures. This includes evaluating the conversion rates to a transfemoral approach. A secondary aim of the study is to assess the radial artery occlusion rates post procedure.
Patients who are undergoing endovascular intervention will be enrolled into the study. Consent will be obtained for the procedure and for the use of their prospectively collected clinical data. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr). If the artery does not meet the size criteria, only a 6Fr sheath will be used, and the data recorded during the procedure will not be utilized for analysis in this study. The preoperative and postoperative care will be the same for all the patients. No tests will be done outside of standard of care.
Patients who are undergoing endovascular intervention will be enrolled into the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).
Device: Transradial approach
Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).
Feasibility of TRA Intervention
The size of the radial artery will be measured and the transradial approach will be used. Notation will be also be recorded if conversion to TFA is used.
Time frame: 1 month
Assess radial artery occlusion rates post procedure
Reverse Barbue Test and ultrasound
Time frame: 1 month
Demographics
Patient demographics will be analyzed such as past medical history, HTN, HLD, Afib
Time frame: 1 month
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Aggregate data will be presented
Ran from Oct 2020 to primary completion in Sep 2022, 23 months.
Of 181 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's 23 months is below that.
Counting every sponsor, half of 199 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →